Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-FUR: trifluridine-tipiracil + fruquintinib vs trifluridine-tipiracil + bevacizumab in refractory metastatic colorectal cancer
ChiCTR2500112138Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in colorectal cancer (CRC) comparing trifluridine-tipiracil + fruquintinib with Control: trifluridine-tipiracil + bevacizumab (2 arms). Primary endpoint: progression-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilfruquintinibbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500112138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112138.